PHS
JAZZ icon

PFM Health Sciences’s Jazz Pharmaceuticals JAZZ Stock Holding History

PFM Health Sciences’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-128,500
Closed -$20.5M – 90
2022
Q4 		$20.5M Buy
+128,500
New +$18.8M 0.73% 52

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PFM Health Sciences's JAZZ Position: Q1 2026 in Review

PFM Health Sciences increased its Jazz Pharmaceuticals (JAZZ) stake by 253% in Q1 2026, buying an estimated $22.3M and bringing the position to 178,144 shares worth $33.7M. The position accounts for 3.07% of the portfolio, ranked #8.

PFM Health Sciences first reported a position in JAZZ in Q1 2015 and has held it in 18 quarters since. The position peaked at $213M in Q2 2018. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • PFM Health Sciences held 178,144 shares of Jazz Pharmaceuticals worth $33.7M as of Q1 2026.
  • PFM Health Sciences bought 127,633 Jazz Pharmaceuticals shares in Q1 2026, an estimated $22.3M.
  • Jazz Pharmaceuticals made up 3.07% of PFM Health Sciences's portfolio in Q1 2026, its #8 holding.
  • PFM Health Sciences first reported a position in Jazz Pharmaceuticals in Q1 2015 and has held it in 18 quarters since.
  • PFM Health Sciences's Jazz Pharmaceuticals position peaked at $213M in Q2 2018.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.